
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals Inc. has demonstrated statistically significant improvements in patient-reported outcomes related to the treatment of paroxysmal supraventricular tachycardia (PSVT), establishing a strong basis for confidence in the commercial viability of its lead product, etripamil. The company is well-positioned for a successful launch, supported by FDA agreement on a streamlined Phase 3 program for atrial fibrillation with rapid ventricular rate (AFib-RVR) and upcoming major medical conferences that may enhance visibility and market engagement. Furthermore, ongoing trials, like NODE-303, continue to reinforce the safety and efficacy of etripamil, suggesting robust potential for value creation as clinical milestones are achieved.
Bears say
Milestone Pharmaceuticals faces a challenging financial outlook due to the underappreciation of its lead product, etripamil, despite its potential benefit in addressing the urgent unmet medical need for patients experiencing paroxysmal supraventricular tachycardia (PSVT). The company's ongoing trials indicate that although etripamil can significantly reduce heart rates rapidly, reliance on medication-based management remains high, with a marked portion of patients not opting for more invasive treatments like catheter ablation. Additionally, market hesitance may be compounded by the overall competitive landscape for cardiovascular drugs and the slow adoption of newer therapies, potentially impeding the company’s revenue generation and stock performance.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares